EVISA Print | Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:

Trivalent Chromium supplemention no help in controlling diabetes

(23.05.2007)


In non-Western diabetic populations, there is some evidence that chromium might be beneficial," Dr. Nanno Kleefstra, told Reuters Health. "In Western populations ... it does not seem to help in the dosages used."

Kleefstra, from Isala Clinics in Zwolle, and colleagues investigated the effects of chromium in people with type 2 diabetes residing in a northern region of the Netherlands. Fifty-seven patients were randomly assigned to take 400 micrograms of chromium per day or a placebo.

After 3 and 6 months of treatment, there were no differences between the chromium group and the placebo group for fasting blood glucose levels, long-term control of glucose levels as measured by A1c, blood pressure, body fat percentage, weight, lipid profile, and how well they responded to the insulin their bodies produced, the investigators report in the medical journal Diabetes Care.

"Especially in Western patients, chromium is not beneficial for improving glycemic control," Kleefstra concluded, probably because most people already get sufficient amounts of chromium.

"It would be interesting to study a deficient population," Kleefstra added. To do so, "I think it is essential to get a tool with which we can detect whether patients are chromium-deficient or not."

SOURCE: Reuters, May 21, 2007


The original study:

N. Kleefstra, S. T. Houweling, S. J.L. Bakker, S. Verhoeven, R. O.B. Gans, B. Meyboom-de Jong, H. J.G. Bilo, Chromium Treatment Has No Effect in Patients With Type 2 Diabetes in a Western Population: A randomized, double-blind, placebo-controlled trial, Diabetes Care, 30/5 (2007) 1092 - 1096. DOI: 10.2337/dc06-2192


Related studies (newest first):

Aviva Levina, Peter A. Lay, Chemical Properties and Toxicity of Chromium(III) Nutritional Supplements, Chem. Res. Toxicol., 21 (2008) 563–571. DOI: 10.1021/tx700385t

Maria A. Andersson, Kierstin V. Petersson Grawe, Oskar M. Karlsson, Lilianne A.G. Abramsson-Zetterberg, Björn E. Hellman, Evaluation of the potential genotoxicity of chromium picolinate in mammalian cells in vivo and in vitro, Food Chem. Toxicol., 45 (2007) 1097–1106. DOI:10.1016/j.fct.2006.11.008

N. Kleefstra, S.T. Houweling, F.G.A. Jansman, K.H. Groenier, R.O.B. Gans, B. Meyboom-de Jong, S.J.L. Bakkeret, H.J.G. Bilo, Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized double-blind, placebo-controlled trial, Diabetes Care 29 (2006) :521–525. DOI: 10.2337/diacare.29.03.06.dc05-1453

D. A. Mark, Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes: Response to Martin et al.,
Diabetes Care, 29/12 (2006) 2764 - 2764. DOI: 10.2337/dc06-1719

J. Martin, D. Matthews, and W. T. Cefalu, Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes: Response to Mark, Diabetes Care, 29/12 (2006) 2764 - 2765.  DOI: 10.2337/dc06-1852

J. Martin, Z. Q. Wang, X. H. Zhang, D. Wachtel, J. Volaufova, D. E. Matthews, and W. T. Cefalu, Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes, Diabetes Care, 29/8 (2006) 1826 - 1832. DOI: 10.2337/dc06-0254



 Related EVISA Resources

Link Database: Chromium in Food


Related EVISA News (newest first)





last time modified: March 9, 2024



Comments






Imprint     Disclaimer

© 2003 - 2024 by European Virtual Institute for Speciation Analysis ( EVISA )